76 related articles for article (PubMed ID: 25189901)
1. Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2014; 28(5):867-70. PubMed ID: 25189901
[TBL] [Abstract][Full Text] [Related]
2. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
3. Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2015; 29(6):687-93. PubMed ID: 26546525
[TBL] [Abstract][Full Text] [Related]
4. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
[TBL] [Abstract][Full Text] [Related]
5. Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Sep; 29(3):2284-90. PubMed ID: 22038727
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
Rubenstein M; Guinan P
In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2013; 30(3):599. PubMed ID: 23677569
[TBL] [Abstract][Full Text] [Related]
8. No compensation in VEGF expression follows antisense suppression of BCL-2 activity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2012; 26(6):937-40. PubMed ID: 23160675
[TBL] [Abstract][Full Text] [Related]
9. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.
Pu YS; Hour TC; Chuang SE; Cheng AL; Lai MK; Kuo ML
Prostate; 2004 Jul; 60(2):120-9. PubMed ID: 15162378
[TBL] [Abstract][Full Text] [Related]
13. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
Jiang H; Xia D; Wu LJ; Chen ZD
Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
[TBL] [Abstract][Full Text] [Related]
15. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
16. Bax expression remains unchanged following antisense treatment directed against BCL-2.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2011 Sep; 28(3):852-8. PubMed ID: 20422317
[TBL] [Abstract][Full Text] [Related]
17. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
18. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Zhang QQ; Wyatt JR; Dean NM
Nat Biotechnol; 1999 Nov; 17(11):1097-100. PubMed ID: 10545916
[TBL] [Abstract][Full Text] [Related]
19. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
20. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
